ArticlePeerJ2026
Correlations between inflammatory biomarkers and clinicopathological features in surgically resected thymic epithelial tumors: implications for preoperative diagnosis.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to analyze the correlations between pathological characteristics, risk factors, and inflammatory biomarkers in patients with thymic epithelial tumors (TETs) undergoing surgical resection. Methods: A retrospective cohort of adult patients with histopathologically confirmed TETs undergoing radical resection between 2015 and 2024 was analyzed. The Kruskal-Wallis test was employed to evaluate associations of systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) with clinical features (age; gender; myasthenia gravis (MG); World Health Organization (WHO) stage; tumor size; Masaoka stage; WHOMScore). A nomogram diagnostic model was constructed to differentiate thymoma from thymic carcinoma. Results: A total of 111 patients (52 males, 59 females) were enrolled, including eight cases of type A thymoma, 38 type AB, nine type B1, 16 type B2, 12 type B3, and 28 thymic carcinomas. Correlations between SII, NLR, PLR, and clinicopathological features (gender, age, MG, tumor size, risk stratification, Masaoka stage, and WHO classification) were analyzed. Significant differences in SII, NLR, and PLR were observed across WHO classifications ( Conclusion: Our findings suggest that inflammatory biomarkers (SII, NLR, and PLR) are significantly associated with the malignancy of TETs. The combination of PLR and MG status may serve as a useful auxiliary tool for distinguishing thymoma from thymic carcinoma, showing potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.